CKD
82
22
26
20
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
4.9%
4 terminated out of 82 trials
83.3%
-3.3% vs benchmark
11%
9 trials in Phase 3/4
20%
4 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 20 completed trials
Clinical Trials (82)
Effects of Dietary Phosphorus on Phosphorus and Calcium Whole-Body Balance and Kinetics in Moderate CKD
Suitability of a High-energy, Low-protein Formula (Renalive® LP)
FAP-targeting PET/CT for Noninvasive Monitoring of Renal Fibrosis
A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis
Serial Biomarker Testing and Cardiovascular Risk Stratification (ACHILLES)
Fib to Alb Ratio in Type 2 Dkd
Fostering Self-Empowerment in CKD Patients Through Food Choice Mapping
Predictors of Rapid CKD Progression
A Multimodal Integrated Intervention for Kidney Cachexia
Digital Care for Holistic Health in Older Adults With Diabetes and Multimorbidity
Self-Management Data and Disease Progression in Chronic Kidney Disease
Real-World Study of Enarodustat for Anemia in Non-Dialysis CKD Patients
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
A Mechanistic Study on the Effect of HTD1801 Versus Placebo on Kidney Function in Patients With Type 2 Diabetes and Chronic Kidney Disease.
Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)
Adia Med of Winter Park LLC Chronic Kidney Disease Research Study
Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)
Early Coronary Angiography in Advanced Chronic Kidney Disease With Acute Coronary Syndrome
Impact of Garlic on the Clinical Outcome in Chronic Hemodialysis Patients
Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial